Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
Lemonaid Health, a subsidiary of 23andMe Holding Co. (Nasdaq: ME), announces its collaboration with Petros Pharmaceuticals (Nasdaq: PTPI) to offer STENDRA® (avanafil), a prescription ED medication, through its telehealth platform. This medication acts within 15 minutes and will be available at improved pricing. With an estimated one in 10 men experiencing ED, this initiative aims to enhance medication accessibility and affordability. Lemonaid Health, which has treated over 200,000 ED patients, provides medication delivery across the U.S. from a 50-state licensed pharmacy. The collaboration aims to offer patients better access to brand-name medications.
- Lemonaid Health's collaboration with Petros Pharmaceuticals expands ED treatment options.
- STENDRA® is fast-acting, working within 15 minutes, enhancing patient satisfaction.
- Improved pricing for STENDRA® makes ED treatment more affordable.
- Lemonaid Health has treated over 200,000 ED patients, demonstrating significant experience.
- Availability of STENDRA® through a 50-state licensed pharmacy increases accessibility.
- Potential side effects of STENDRA® include headache, flushing, nasal congestion, and back pain.
- STENDRA® is contraindicated with organic nitrates and guanylate cyclase stimulators.
- Combination with other PDE5 inhibitors or erectile dysfunction therapies is not recommended.
- Use of STENDRA® with alcohol, alpha-blockers, or antihypertensives may lead to hypotension.
- STENDRA® is not safe or effective for women or children.
Insights
Lemonaid Health expanding its offerings to include STENDRAⓇ signifies a strategic move towards enhancing their product line in the telemedicine space. For 23andMe Holding Co. (ME), this could potentially drive revenue growth through increased customer acquisition, given the high prevalence of ED. The collaboration with Petros Pharmaceuticals (PTPI) indicates a mutually beneficial partnership that may enhance both companies' market positions.
Moreover, by offering a branded medication at a lower cost, Lemonaid Health may attract a price-sensitive demographic, potentially increasing their market share. The fact that Lemonaid has treated over 200,000 patients suggests a solid existing customer base, which could lead to an immediate uptake of the new offering. However, the degree to which this impacts financials will depend on the pricing structure, uptake rates and the effectiveness of their marketing strategy.
In the short-term, this partnership may boost stock performance due to increased investor confidence in both companies' growth prospects. In the long-term, the success hinges on maintaining competitive pricing and ensuring high levels of customer satisfaction and retention.
Adding STENDRAⓇ to Lemonaid Health’s roster could significantly impact the telehealth landscape. STENDRAⓇ is known for its rapid onset (about 15 minutes) which offers an edge over other ED medications. This feature can be a important differentiator in a competitive market. However, appropriate patient screening is necessary to avoid contraindications, particularly with medications like nitrates and alpha-blockers.
The potential for adverse reactions, such as headaches and flushing, needs careful management. While these issues are common with PDE5 inhibitors, the lower discontinuation rates in clinical trials indicate good tolerability. For Lemonaid Health, ensuring that patients are well-informed about potential side effects and interactions will be important in maintaining high patient satisfaction and trust.
By facilitating discreet access to ED treatment, Lemonaid Health addresses a significant barrier to care, potentially improving overall treatment adherence. This strategic addition could thus play a critical role in advancing telehealth's position in managing chronic conditions.
The introduction of an affordable, fast-acting ED medication like STENDRAⓇ through a telehealth platform can be seen as a significant market differentiator for Lemonaid Health. Given the stigma attached to ED, the discreet nature of telemedicine can be appealing to a large segment of the male population. This partnership could position Lemonaid Health as a leader in online ED treatment solutions, potentially capturing a significant market share from traditional healthcare providers.
From a competitive standpoint, this move could compel other telehealth providers to seek similar partnerships or enhance their own offerings, leading to a more dynamic and potentially fragmented market. For Petros Pharmaceuticals, this collaboration could lead to increased brand recognition and product adoption, assuming Lemonaid’s platform effectively markets and distributes STENDRAⓇ.
In the long-term, the success will depend on patient retention and the perceived value of telehealth services over in-person consultations. Effective marketing and continuous improvements in the telehealth experience will be important to sustaining growth and gaining a competitive edge.
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform.
Working directly with STENDRAⓇ manufacturer Petros Pharmaceuticals, Lemonaid Health is able to offer the fast-acting ED medication at improved pricing. With one in 10 men estimated to have ED at some point in their lifetime1, Lemonaid Health clinicians are able to evaluate and prescribe patients a variety of ED medications at various price points and doses.
“We look forward to working directly with pharmaceutical manufacturers like Petros to offer our patients improved prices and better access to brand name medications across our telemedicine offerings,” said Eland Siddle, Head of Pharmacy, Lemonaid Health. “Adding STENDRAⓇ to our ED medication offerings, gives patients more options when it comes to finding the right medication for their needs.”
Lemonaid Health services patients across the United States, and has treated over 200,000 ED patients to date. It provides access to medication delivery from a 50 state licensed pharmacy, which has the potential to help millions of men discreetly and legally obtain a treatment for a still significantly undertreated condition.
Important Safety Information about STENDRA® (avanafil)
STENDRA® (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction. STENDRA is not for use in women or children. It is not known if STENDRA is safe and effective in women or children under 18 years of age. A 100-mg and 200-mg tablet can be taken as early as ~15 minutes before sexual activity. STENDRA only works with sexual stimulation and should not be taken more than once a day. STENDRA can be taken with or without food; do not drink too much alcohol when taking STENDRA (for example, more than 3 glasses of wine or 3 shots of whiskey) as it can increase chances of side effects. Of people enrolled in clinical trials,
STENDRA is contraindicated with any form of organic nitrates, in patients with known hypersensitivity to any component of the tablet, and in patients who are using a guanylate cyclase stimulator.
Patients should not use STENDRA if sexual activity is inadvisable due to cardiovascular status or any other reason. Before taking STENDRA tell your doctor if you have had any kind of heart issues including heart attack, heart failure, angina and irregular heartbeat or have elevated or low blood pressure.
Use of STENDRA with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension.
Patients should seek emergency treatment if an erection lasts greater than 4 hours.
Patients should stop STENDRA and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of Non Arteritic Ischemic Optic Neuropathy (NAION). Discuss with patients the increased risk of NAION in patients with a history of NAION.
Patients should stop taking STENDRA and seek prompt medical attention in the event of sudden decrease or loss of hearing.
STENDRA can potentiate the hypotensive effect of nitrates, alpha blockers, antihypertensives, and alcohol. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin) increase STENDRA exposure.
Combination with Other PDE5 Inhibitors or Erectile Dysfunction Therapies is not recommended.
The safety of STENDRA is unknown in patients with bleeding disorders and patients with active peptic ulceration.
The use of STENDRA offers no protection against sexually transmitted diseases including HIV. Consider counseling patients on protective measures for sexually transmitted diseases.
The most common adverse reactions reported with use of STENDRA include headache, flushing, nasal congestion, nasopharyngitis, and back pain.
For more information about STENDRA, call 844-458-4887. If you would like to report an adverse event or product complaint, please contact us at 844-458-4887.
You are encouraged to report negative side effects of prescription drugs to the FDA by calling 1-800-FDA-1088, or at www.fda.gov/medwatch.
Please see the full Prescribing Information and Patient Information.
About Lemonaid Health
Lemonaid Health, part of the 23andMe family, provides online telemedicine services in all 50 states and D.C. through its affiliated medical groups (subject to local laws). Prescriptions require completion of an independent medical consultation with a licensed healthcare provider through the Lemonaid online platform. Medications are only available if prescribed. Visit www.lemonaidhealth.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
Contacts
Investor Relations Contact: investors@23andMe.com
Media Contact: press@23andMe.com
1 Cleveland Clinic, 2019
FAQ
What is the new ED medication offered by Lemonaid Health?
How quickly does STENDRA® work?
What company is collaborating with Lemonaid Health to offer STENDRA®?
Is STENDRA® available across the United States?
What are the common side effects of STENDRA®?
